Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-059793

Regulus Therapeutics Inc. · RGLS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Period of report
Nov 12, 2018
Accepted (ET)
Nov 21, 2018 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001505512

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2Nov 12, 2018A20,910—A168,672D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2,F4,F3$31.92Nov 12, 2018D152D—Feb 8, 2022Common Stock1520D
Stock Option (Right to Buy)F2,F4,F3$111.84Nov 12, 2018D1,458D—Jun 9, 2023Common Stock1,4580D
Stock Option (Right to Buy)F2,F4,F3$74.64Nov 12, 2018D1,458D—May 21, 2024Common Stock1,4580D
Stock Option (Right to Buy)F2,F4,F3$120.24Nov 12, 2018D1,458D—Jun 8, 2025Common Stock1,4580D
Stock Option (Right to Buy)F2,F4,F3$74.40Nov 12, 2018D3,051D—May 31, 2026Common Stock3,0510D
Stock Option (Right to Buy)F2,F4,F3$17.40Nov 12, 2018D2,500D—May 30, 2027Common Stock2,5000D
Stock Option (Right to Buy)F2,F4,F5$8.52Nov 12, 2018D6,250D—May 16, 2028Common Stock6,2500D
Stock Option (Right to Buy)F2,F4,F6$8.76Nov 12, 2018D4,583D—May 31, 2028Common Stock4,5830D

Explanation of responses